TISSUE REPAIR LIMITED (TRP)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

TRP - TISSUE REPAIR LIMITED

Year End: June
GICS Industry Group : NONE
Debt/EBITDA: -0
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.25

19 Jul
2024

0.000

OPEN

$0.25

0.000

HIGH

$0.25

8

LOW

$0.25

OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NEU . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SPL . TLX . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
TRP: 1
Title FY22
Actual
FY23
Actual
FY24
Forecast
FY25
Forecast
EPS (cps) xxx - 6.9 N/A xxx
DPS (cps) xxx 0.0 N/A xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

0.00

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 202120222023
EPS Basic xxxxxx-6.9
DPS All xxxxxx0.0
Sales/Revenue xxxxxx0.0 M
Book Value Per Share xxxxxx36.2
Net Operating Cash Flow xxxxxx-4.3 M
Net Profit Margin xxxxxx-135,709.17 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202120222023
Return on Capital Employed xxxxxx-17.68 %
Return on Invested Capital xxxxxx-17.68 %
Return on Assets xxxxxx-17.29 %
Return on Equity xxxxxx-17.68 %
Return on Total Capital xxxxxx-24.31 %
Free Cash Flow ex dividends xxxxxx-4.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202120222023
Short-Term Debt xxxxxx0 M
Long Term Debt xxxxxx0 M
Total Debt xxxxxx0 M
Goodwill - Gross xxxxxx-
Cash & Equivalents - Generic xxxxxx21 M
Price To Book Value xxxxxx0.75

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202120222023
Capex xxxxxx0.0 M
Capex % of Sales xxxxxx72.95 %
Cost of Goods Sold xxxxxx0 M
Selling, General & Admin. Exp & Other xxxxxx6 M
Research & Development xxxxxx3 M
Investments - Total xxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

0
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

01/03/2024

-1

No Rating

-

Morgans highlights Tissue Repair finished the 1H with sufficient capital ($19.3m) to fund its clinical program, despite a net loss of -$2.3m. This outcome compares to the -$3.2m loss in the previous corresponding period.

The company's cosmetic gel product TR Pro+ was launched in the period with initially positive feedback, notes the analyst.

Management expects the Phase 3 trial for venous leg ulcers will start recruiting in the 1Q of FY25, a slight delay on the original date within the 4Q of FY24.

Morgans no longer provides a rating, valuation or forecast for Tissue Repair.

EXPERT VIEWS
Display All Commentary

No. Of Recommendations

0
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

TRP STOCK CHART